NCT06389474招募中3 期
A Phase III Study to Evaluate the Efficacy of INM004 (Shiga Antitoxin) in Pediatric Patients With Shiga Toxin-producing Escherichia Coli-associated Hemolytic Uremic Syndrome.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 220
- 试验地点
- 58
- 主要终点
- Time to recovery of renal function during the acute phase
研究概览
简要总结
The objectives of this study are to evaluate the efficacy, safety, and pharmacokinetics of INM004 in pediatric patients with Hemolytic Uremic Syndrome associated to infection by Shiga toxin-producing Escherichia coli (STEC-HUS).
详细描述
The primary objective will be to evaluate the efficacy of INM004, added to the standard of care, as a treatment for STEC-HUS in the amelioration of renal function.
Secondary objectives
- To evaluate the efficacy of INM004 in the reduction of mortality.
- To evaluate the efficacy of INM004 in the prevention and reduction of extrarenal complications.
- To evaluate the efficacy of INM004 in the improvement of TMA laboratory parameters.
- To evaluate the efficacy of INM004 in the reduction of hospital stay days.
- To evaluate the safety of INM004
- To evaluate the pharmacokinetics of INM004
- To evaluate the kinetics of Stx
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 9 Months 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 9 months and < 18 years at the time of randomization.
- •In addition, only for subjects < 1 year and ≥ 15 years, confirmation of STEC infection determined by:
- •Detection of generic Stx, Stx1, Stx2, or Stx1/Stx2 in stools by enzyme immunoassay (EIA); or
- •Detection of stx, stx1, stx2, or stx1/stx2 genes in stools by Polymerase Chain Reaction (PCR); or
- •Detection of specific anti-polysaccharide (IgM) antibodies in serum; or
- •Fecal culture positive for E. coli O157 confirmed by serogroup-specific seroagglutination.
- •Hospitalization at the participating institution.
- •History of onset of diarrhea within 10 days prior to STEC-HUS diagnosis at the participating institution.
- •Diagnosis of STEC-HUS defined as a subject with signs of renal damage, hemolysis, and platelet consumption:
- •Signs of renal damage defined as:
- •Serum creatinine value above the ULN for age and sex, and GFR below the LLN for age, sex, and height.
- •Presence of hemolysis documented by:
- •LDH levels above the ULN for age, and/or
- •Presence of schistocytes in peripheral blood smear.
- •Platelet consumption according to any of the following laboratory criteria:
- •Peripheral blood platelet count < 150 × 103/μL, and/or
- •A ≥50% decrease in peripheral blood platelet count compared to a sample collected within the previous 24 hours.
- •Informed consent form signed and dated by the subject or, the legal guardian(s), with the subject's assent as appropriate based on age and regulatory guidelines in the region.
- •Subjects who have already had menarche must have a negative pregnancy test.
排除标准
- •Start of dialysis within 48 hours prior to admission to the participating institution.
- •More than 24 hours from diagnosis of STEC-HUS at the participating institution up to randomization.
- •History of chronic/recurrent hemolytic anemia, thrombocytopenia, or CKD.
- •Personal and/or family history of atypical HUS.
- •Suspected HUS secondary to infectious processes other than gastrointestinal (e.g., Streptococcus pneumoniae, HIV).
- •Suspected HUS secondary to other etiologies (e.g., drug-associated HUS, neoplasms, bone marrow or solid organ transplantation, autoimmune disorders).
- •Any other acute or chronic medical condition that, in the opinion of the investigator, may interfere with the evaluation of the efficacy and/or safety of the study medication.
- •History of: a) anaphylaxis of any kind; b) prior administration of equine serum (e.g., antivenom, anti-arachnid serum, anti-SARS-CoV-2 serum, etc.) or an allergic reaction from contact or exposure to horses.
- •Pregnant or breastfeeding woman.
- •Impossibility of hospitalization in the participating institution.
- •Concurrent participation in another clinical trial or having participated in a clinical trial in the last 3 months.
- •Severe malnutrition. Defined when the weight is three standard deviations below the median, according to height, age and sex as per WHO guidelines.
- •Medical conditions that may affect kidney function or cause/enhance neurological symptoms or signs:
- •Congenital or acquired anomalies that may affect functioning renal mass.
- •Epilepsy or structural abnormalities of the brain that may increase the risk of seizures.
- •Prematurity (born before 28 weeks gestation).
- •Other (according to investigator criteria).
研究组 & 干预措施
INM004
Experimental
Two doses of Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab´)2 fragment at a dosage of 4 mg/kg of body weight, 24 hours apart.
干预措施: INM004 (Biological)
Placebo
Placebo Comparator
Two doses of saline solution, 24 hours apart.
干预措施: Placebo (Other)
结局指标
主要结局
Time to recovery of renal function during the acute phase
时间窗: 28 days
Time (days) to achieve a glomerular filtration rate greater than or equal to the lower limit of normal (according to age, height, and sex) and a serum creatinine lower than or equal to the upper limit of normal (according to age and sex), both measured in the absence of dialysis.
次要结局
- Short-term recovery of renal function(90 days)
- Dialysis requirement(90 days)
- MAKE 90(90 days)
- Mortality(90 days)
- Dialysis longer than 10 days(90 days)
研究者
研究点 (58)
Loading locations...
相似试验
尚未招募
1 期
A Clinical Study of Injectable IMM0306 in Combination With LenalidomideB-cell Non-Hodgkin's LymphomaNCT05771883ImmuneOnco Biopharmaceuticals (Shanghai) Inc.102
进行中（未招募）
3 期
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of AgeCystic FibrosisNCT05422222Vertex Pharmaceuticals Incorporated210
进行中（未招募）
3 期
A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous NephropathyPrimary Membranous NephropathyNCT05862233Beijing Mabworks Biotech Co., Ltd.150
Unknown
3 期
Clinical Trials to Assess the Efficacy and Safety of HLIMAcute Upper Respiratory Tract InfectionAcute BronchitisNCT03827590SamA Pharmaceutical Co., Ltd487
已完成
3 期
Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria PatientsFalciparum MalariaNCT00403260Medicines for Malaria Venture1,271